Tenax Therapeutics/ US88032L6056 /
22/05/2024 21:15:43 | Chg. -0.12 | Volume | Bid- | Ask- | High | Low |
---|---|---|---|---|---|---|
3.65USD | -3.18% | 12 Turnover: 43.82 |
-Bid Size: - | -Ask Size: - | 3.66 | 3.65 |
GlobeNewswire
14/05
Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update
GlobeNewswire
30/04
Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertens...
GlobeNewswire
09/04
Tenax Therapeutics to Host KOL Event: “LEVEL Setting: the Scientific Rationale for Levosimendan as a...
GlobeNewswire
28/03
Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial ...
GlobeNewswire
29/02
Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT ...
GlobeNewswire
20/02
Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimen...
GlobeNewswire
08/02
Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering
GlobeNewswire
08/02
Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimenda...
GlobeNewswire
06/02
Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significa...
GlobeNewswire
17/11/2023
Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific ...
GlobeNewswire
13/11/2023
Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment ...
GlobeNewswire
04/01/2022
Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs